Clinical prospective study to investigate efficacy of NK cell therapy for malignant tumors.
Not Applicable
- Conditions
- Malignant tumor
- Registration Number
- JPRN-UMIN000008046
- Lead Sponsor
- Seta Clinic Group
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
Not provided
Exclusion Criteria
Patients who have: (1) Pulmonary fibrosis or interstitial pneumonia, or history or predisposition of them; (2) Serious drug allergy; (3) Positive for HIV or HTLV-1; (4) Active autoimmune disease; (5) Continuous systemic administration of steroids; (6) Other cancers; (7) Active infections; (8) Pregnant or lactating; (9) T cell, NK cell lymphoma and leukemia; (10) Serious cardiac disease; (11) Any reason why, in the opinion of the investigator, the patient should not participate.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method